Lupus Science & Medicine

Article	Citations
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	224
Genetic load in incomplete lupus erythematosus	62
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	50
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	49
Towards a minimal core dataset for systemic lupus erythematosus studies	46
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	44
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	42
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	39
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	37
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	37
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	32
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	29
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	29
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus	28
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort	26
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	25
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	24
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus	23
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	23
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	22
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	22
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	21
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial	21
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus	20
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	20

Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated	20
Cortical changes in women with systemic lupus erythematosus with mild cognitive impairment: a voxel-based morphometry and surface-based morphometry study	20
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice	20
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA	20
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression	19
Frequency-dependent and temporal variability of low-frequency fluctuations in patients with primary Sjögren’s syndrome	19
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	18
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis	18
Prevalence and determinants of vertebral fractures in a SLE cohort	17
Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts	17
Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort	16
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden	16
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus	16
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study	16
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE	16
Dyspigmentation and scarring in cutaneous lupus erythematosus	15
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler	15
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE	15
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis	15
Canadian patient experiences of lupus nephritis: a qualitative analysis	15
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond	15
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis	15
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development	15
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort	15
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups	14
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus	14
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus	14
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway	14
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus	14
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE	13
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus	13
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study	13
Lupus spectrum ambiguity has long-term negative implications for patients	12
Discrepant anti-dsDNA testing between EliA and Crithidia in ANA negative samples: just a false positive?	12
Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes	12
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P a	12
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study	12
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE	12
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE	12
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus	12
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA	12
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework	12
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	11
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)	11
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study	11
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas	11
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms	11
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus	11
Potential causal effect of SLE on osteoporosis, and the mediation effect: a Mendelian randomisation study	11
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption	11

Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study	11
Visceral fat, cardiovascular risk factors and quality of life in lupus activity categorised via complement C3	10
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	10
Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease	10
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	9
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history	9
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	9
Validation of eight endotypes of lupus based on whole-blood RNA profiles	9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	9
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database	9
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway	9
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE	9
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis	9
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	9
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort	9
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus	9
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms	9
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry	9
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	9
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	9
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study	9
Investigations into SCAMP5, a candidate lupus risk gene expressed in plasmacytoid dendritic cells	9
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis	9
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	9
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	8
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	8
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus	8
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen	8
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week p	8
Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vas	8
Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus	8
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE	8
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations	8
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	8
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort	8
Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life	7
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data	7
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients	7
HDAC3 knockdown inhibits ferroptosis via upregulating Nrf2 to alleviate renal interstitial fibrosis in lupus nephritis	7
Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE	7
Assessing grey matter structural alterations in systemic lupus erythematosus using synthetic MRI	7
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study	7
Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database	7
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study	7
Immunogenicity, safety and adverse events of sequential vaccination with a 10-valent pneumococcal conjugate vaccine (PCV10) and PPSV23 compared with PPSV23 alone in systemic lupus erythematosus	6
Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA	6
Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse	6
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies	6
Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus	6
Prevalence of major adverse cardiovascular events among Saudi patients with systemic lupus erythematosus compared with the general population: updates from the national SLE and PURE cohorts	6
Social Factors, Epigenomics and Lupus in African American Women (SELA) Study: protocol for an observational mechanistic study examining the interplay of multiple individual and social factors on lupus	6
Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus	6
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis	6
Systemic lupus in the era of machine learning medicine	6
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic	6
Machine learning-based identification of novel hub genes associated with oxidative stress in lupus nephritis: implications for diagnosis and therapeutic targets	6
Association of phenotypic frailty and hand grip strength with telomere length in SLE	6
Effects of dual-task exercises on cognitive status, disease activity and quality of life in childhood-onset systemic lupus erythematosus	6
Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China	6
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus	6
Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis	6
NLR outperforms PLR in SLE diagnosis and prognosis: an AI-enhanced meta-analysis of 12 850 patients with ethnicity-specific cut-offs	6
Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage	5
Does social support reduce bodily pain among African American women with SLE? Findings from a randomised controlled trial	5
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis	5
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis	5
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	5
Epidemiology of patients with moderate-to-severe SLE in Sweden	5
Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis	5
Celastrol ameliorates lupus by promoting apoptosis of autoimmune T cells and preventing autoimmune response in MRL/lpr mice	5
Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study	5
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study	5
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	5
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus	5
Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	5
Predictors of patient-reported outcomes phenotypes in SLE during remission: a cluster analysis approach	5
Activation-induced colocalisation of SCAMP5 with IFNα in human plasmacytoid dendritic cells	5
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology	5
Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype	5
Development of a predictive model for systemic lupus erythematosus incidence risk based on environmental exposure factors	5

Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data	4
Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries	4
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE	4
5-Hydroxymethylcytosine in circulating cell-free DNA as a potential diagnostic biomarker for SLE	4
Abnormally high expression of D1-like dopamine receptors on lupus CD4+ T cells promotes Tfh cell differentiation	4
p16Ink4a, a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3 mouse model of lupus	4
Correction: Differences in reproductive health discussions in an urban hispanic population with SLE: lessons from the field	4
Multidisciplinary re-evaluation of neuropsychiatric events to confirm the neuropsychiatric lupus diagnosis at an Indonesian tertiary hospital	4
Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis	4
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis	4
Failing maternal–fetal tolerance in SLE (FaMaLE): a prospective cohort study for finding the molecular mechanisms behind pregnancy complications	4
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective	4
Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study	4
Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis	4
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	4
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol	4
Myocardial Performance Index to assess cardiac function in autoimmune connective tissue disease: a systematic review and meta-analysis	4
Association of genetic variation on X chromosome with systemic lupus erythematosus in both Thai and Chinese populations	4
Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity	4
Prevalence and incidence of systemic lupus erythematosus in Thailand based on national health data	4
Next generation sequencing analysis reveals complex genetic architecture of childhood-onset systemic lupus erythematosus	4
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial	4
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Stu	4
Immune-mediated thrombotic thrombocytopenic purpura with systemic lupus erythematosus: clinical features and outcome	4
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus	4
Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research	3
Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage	3
Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials	3
Association of patient copayment and medication adherence in systemic lupus erythematosus	3
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial	3
Immune gene expression and functional networks in distinct lupus nephritis classes	3
Using photovoice to investigate patient experiences of lupus nephritis in Canada	3
Rural–urban disparities in hospitalisation for myocardial infarction in systemic lupus erythematosus in the USA	3
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials	3
Alignment of contraception use with the ACR reproductive health guidelines in women with systemic lupus erythematosus within the RISE registry	3
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis	3
Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis	3
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA	3
Metabolomic analysis suggests thiamine monophosphate as a potential marker for mesenchymal stem cell transplantation outcomes in patients with SLE	3
Medication-related hospitalisations in patients with SLE	3
Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study	3
Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy	3
Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus	3
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus	3
Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases	3
Informing trial measurement in systemic lupus erythematosus: frequency of domain-specific disease activity in a multinational cohort	3
Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus	3
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus	3
Epidemiology of SLE in Italy: an observational study using a primary care database	3
2021 DORIS definition of remission in SLE: final recommendations from an international task force	3
Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study	3
Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients	3
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS	3
Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study	3
Comparison of TLR4, NF-κB and IRF3 expression in kidney tissue between lupus nephritis (LN) and systemic lupus erythematosus (SLE): a pristane-induced lupus mice model study	3
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study	3
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis	3
Detection rate, demographic associations and clinical implications of anti-C1q antibody elevations across diverse disease states	3